Graft PD-L1 as a predictive marker for rejection in PD-1 inhibitor therapy for recurrent liver tumors post-transplant: A prospective pilot trial
{{output}}
The safety of immunotherapy in transplant patients remains unclear due to rejection risks. This study assessed the safety and efficacy of programmed death-1 (PD-1) inhibitors in post liver-transplantation patients with recurrent tumors, emphasizing the value o... ...
